Xtandi 80 MG tablet 60S
Ended Awarded
- Contract number
- SPE2DB25FJGEX
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $4,170
Award facts
- Contract value 100% obligated
- $4,169.59 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order on April 23, 2025, by the Defense Logistics Agency to supply 60 tablets of Xtandi 80 mg at a firm fixed price of $4,169.59. This award represents a single delivery order issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA's SPE2DB program, valued at approximately $500 million through November 2026. The contract carries no set-aside designation, demonstrating the company's competitive standing in federal pharmaceutical procurement markets. Xtandi is an oncology treatment medication, consistent with DMS Pharmaceutical Group's established role in supplying specialized pharmaceutical products to military and federal healthcare facilities nationwide.
This delivery order exemplifies the operational structure of the broader SPE2DB contract, which authorizes DLA to issue firm fixed-price orders for pharmaceutical items supporting medical supply needs across Department of Defense healthcare sites globally. DMS Pharmaceutical Group has maintained a robust contract portfolio with DLA, securing multiple awards for prescription medications, biologics, and medical consumables without relying on set-aside restrictions. The company's capabilities span branded and generic drugs, over-the-counter medications, and specialty pharmaceutical products, positioning it as a critical supplier within the federal pharmaceutical supply chain for military health operations.
Quick answers
Who was awarded contract SPE2DB25FJGEX?
SPE2DB25FJGEX was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on April 23, 2025.
How much is contract SPE2DB25FJGEX worth?
The government has obligated $4,170 on SPE2DB25FJGEX.
Is contract SPE2DB25FJGEX an order under another contract?
Yes. SPE2DB25FJGEX is a delivery order under SPE2DB24D9224, an indefinite delivery contract.
Was contract SPE2DB25FJGEX competed?
The extent of competition for SPE2DB25FJGEX was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award